search
Back to results

ImpleMEntation of a Digital-first Care deLiverY Model for Heart Failure in Uganda (MEDLY Uganda)

Primary Purpose

Heart Failure

Status
Not yet recruiting
Phase
Not Applicable
Locations
Uganda
Study Type
Interventional
Intervention
Enhanced HF Clinical Care (Core-HF)
Digital health intervention (Medly Uganda) plus enhanced HF clinical care (Core-HF)
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Heart Failure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Clinical diagnosis of New York Heart Association (NYHA) Class II-III HF Access to a mobile phone Basic reading skills in 1 of the offered languages, as determined by their clinical care provider. Languages will include: Lusoga in Jinja, Runyankole in Mbarara, Luganda in Masaka, Rutooro in Fort Portal, Acholi in Gulu, and Alur in Lira in addition to English. Exclusion Criteria: Any individual not meeting the above inclusion criteria Inability to provide informed consent, as determined by the nurse manager Active medical condition requiring hospitalization, such as cardiac ischemia (acute electrocardiographic changes and/or positive biomarkers, if available), syncope, or significant fluid overload Echocardiography findings that do not support a diagnosis of HF as determined during a study visit. This exclusion might occur following enrollment and new patients will be consented and enrolled to compensate for these exclusions.

Sites / Locations

  • Fort Portal Regional Referral Hospital
  • Gulu Regional Referral Hospital
  • Jinja Regional Referral Hospital
  • Lira Regional Referral Hospital
  • Masaka Regional Referral Hospital
  • Mbarara Regional Referral Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Step 1. Core HF intervention period

Step 2. Core-HF plus Medly Uganda digital health intervention

Arm Description

All sites will be trained in an evidence-based clinical care bundle for HF, to ensure standardized basic HF care across the participating RRHs in the study. For this service bundle which will augment self-care (Core-HF), the investigators will train providers in an evidence-based HF clinical care service bundle including a care protocol (treatment algorithm for HF), self-care training for patients and providers, and medication stock management prior to introducing the digital health intervention (Medly Uganda, described in Arm 2).

Medly Uganda will utilize a patient-facing mobile health application designed to improve self-care among patients with HF. Its principal components are: 1) a patient-facing mobile application that processes patient-reported symptoms and generates algorithm-driven messages to guide self-care and symptom management and 2) a clinician- facing internet dashboard that monitors symptom reports and facilitates nurse-guided management recommendations and physician backup support. The project will support an integrated, digital interface at participating hospitals to monitor and intervene with patients who are using the mobile health application.

Outcomes

Primary Outcome Measures

Change in Self-Care of Heart Failure Index (SCHFI)
The SCHFI v7.23 is a validated 39-item instrument hat assesses maintenance, management, and self-confidence of heart failure self-care. Scores range from 0-100 with higher scores indicating improved self care.
Clinical Effectiveness
A composite of the number of participants with mortality and HF hospitalization will be used to assess clinical effectiveness. This outcome is the most widely used composite clinical endpoint in HF trials globally.

Secondary Outcome Measures

Participant fidelity to self-care assessed by medication adherence
Participant fidelity will be assessed by self report administered by the Research Assistant.
Participant fidelity to self-care assessed by optimal HF medication dosing
Participant fidelity to self-care assessed by the percentage of participants that achieve optimal HF medication dosing assessed by self report
Participant fidelity to self-care assessed by self report
Participant fidelity to self-care assessed by self reported adherence to dietary sodium restriction and exercise recommendations
Facility fidelity to implementation strategy assessed by vital sign checks
Facility fidelity to implementation strategy will be assessed by the percentage of participants receiving vital sign checks
Change in blood pressure
Facility fidelity to implementation strategy will be assessed by change in blood pressure. Lower blood pressure indicates a positive outcome.
Change in weight
Facility fidelity to implementation strategy will be assessed by change in weight measured in pounds. Lower weight indicates a positive outcome.
Change in resting pulse
Facility fidelity to implementation strategy will be assessed by change in resting pulse measured in beats per minute. Slower pulse indicates a positive outcome.
Percentage of planned echo training sessions conducted with post-training participant feedback
Facility fidelity to implementation strategy will be assessed by the percentage of planned echo training sessions conducted with post-training participant feedback
Facility fidelity to implementation strategy assessed by the adherence to medications
Facility fidelity to implementation strategy will be assessed by the prescribing-to-dispensing ratio of HF medications at facility pharmacy by self report
Change in 6-minute walk test
The 6-minute walk test monitors physical conditioning. It measures the distance an individual can walk over a total of six minutes on a hard, flat surface. The individual can self-pace and rest as needed as they walk back and forth along a marked course. The participant can use an assistive walking device they normally use, such as a cane. The minimum clinically important difference in 6-minute walk distance is approximately 30 meters, a difference that is associated with mortality.
Change in Pro-NT Brain Natriuretic Peptide (Pro-NT BNP)
Levels of Pro-NT BNP, a widely used prognostic marker in HF, will be measured in blood samples in pg/mL. Lower values indicate a positive outcome.
Change in Left Ventricular Ejection Fraction
Left ventricular ejection fraction (LVEF) is a widely-recognized clinical prognostic marker for heart failure patients. It is measured as a percentage. Possible range is 0-100. Low is <50%. High is >=50%. LVEF is measured by echocardiogram using Simpson biplane formula
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ)
The KCCQ is a 12-item questionnaire that measures symptoms, physical and social limitations, and quality of life in participants with heart failure. KCCQ scores are scaled from 0 to 100, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent.
Change in EuroQol -5D (EQ-5D)
EQ-5D 5L is a standardized participant completed questionnaire that measures health-related quality of life. It is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions. A utility score was obtained by using a weighted combination of the levels of the five dimension-scales.
Change in Patient Health Questionnaire-9 (PHQ-9)
Health-related quality of life will be assessed using the PHQ-9. PHQ-9 is a 9-item validated questionnaire used to screen for depression with a range of scores from 0-45. A cumulative score of ≥10 is considered positive with lower scores indicating no or mild anxiety.

Full Information

First Posted
July 13, 2023
Last Updated
October 12, 2023
Sponsor
Yale University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT05955937
Brief Title
ImpleMEntation of a Digital-first Care deLiverY Model for Heart Failure in Uganda
Acronym
MEDLY Uganda
Official Title
ImpleMEntation of a Digital-first Care deLiverY Model for Heart Failure in Uganda
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 2024 (Anticipated)
Primary Completion Date
August 2027 (Anticipated)
Study Completion Date
August 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a stepped wedge, cluster-randomized study, that will implement a digital-first, multi-component strategy for Heart Failure (HF) to improve HF self-care at 6 Regional Referral Hospital (RRH) outpatient departments in Uganda. The investigators will evaluate both implementation and clinical outcomes using mixed methods. . First, investigators will assess the implementation and clinical effectiveness of an enhanced standard-of-care clinical bundle, and a digital health intervention to improve HF self-care in Uganda (Aim 1). To do this, the investigators will conduct a stepped-wedge, cluster randomized trial that includes a brief control period followed by a clinical care service bundle for HF (Core HF), followed by the introduction of the digital health application (Medly Uganda). The co-primary outcomes will be the Self-Care of HF Index (implementation) and the composite of mortality and HF hospitalization (clinical effectiveness). To ensure standardized basic HF care which will augment self-care, investigators will train providers in an evidence-based HF clinical care service bundle (Core HF) including a care protocol (treatment algorithm for HF), self-care training for patients and providers, and medication stock management prior to the introduction of the digital health intervention (Medly Uganda). Medly Uganda will utilize a patient-facing mobile health application designed to improve self-care among patients with HF. Its principal components are: 1) a patient-facing mobile application that processes patient-reported symptoms and generates algorithm-driven messages to guide self-care and symptom management and 2) a clinician-facing internet dashboard that monitors symptom reports and facilitates nurse-guided management recommendations and physician backup support. The project supports an integrated, digital interface at participating hospitals to monitor and intervene with patients using the mobile health application.
Detailed Description
In parallel to the above, the investigators will conduct a mixed methods process evaluation to inform iterative adjustments to the implementation processes, i.e., a Learn- As-You-Go design by reviewing qualitative feedback and quantitative intervention data (Aim 2). Then, cost effectiveness, and sustainability factors for Medly Uganda, including an examination of cost, cost-effectiveness, and equity of Medly Uganda from a financial and societal perspective will be explored (Aim 3). The focus of this registration will be Aim 1 and Aim 2.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
After 1-2 month-long run-in periods to allow for integration and adoption of the interventions all sites will receive the multi-component implementation strategy, beginning with the Core HF and followed by Medly Uganda. Sites will be randomized using a randomization software to receive the interventions at different start points within the first six months, for varying durations throughout the 3-year study period.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
575 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Step 1. Core HF intervention period
Arm Type
Experimental
Arm Description
All sites will be trained in an evidence-based clinical care bundle for HF, to ensure standardized basic HF care across the participating RRHs in the study. For this service bundle which will augment self-care (Core-HF), the investigators will train providers in an evidence-based HF clinical care service bundle including a care protocol (treatment algorithm for HF), self-care training for patients and providers, and medication stock management prior to introducing the digital health intervention (Medly Uganda, described in Arm 2).
Arm Title
Step 2. Core-HF plus Medly Uganda digital health intervention
Arm Type
Experimental
Arm Description
Medly Uganda will utilize a patient-facing mobile health application designed to improve self-care among patients with HF. Its principal components are: 1) a patient-facing mobile application that processes patient-reported symptoms and generates algorithm-driven messages to guide self-care and symptom management and 2) a clinician- facing internet dashboard that monitors symptom reports and facilitates nurse-guided management recommendations and physician backup support. The project will support an integrated, digital interface at participating hospitals to monitor and intervene with patients who are using the mobile health application.
Intervention Type
Other
Intervention Name(s)
Enhanced HF Clinical Care (Core-HF)
Intervention Description
All clinical care providers involved in HF care at participating RRHs will be trained in a HF service bundle including a care protocol (treatment algorithm based on global guidelines), self-care training for patients and providers, and medication stock management to ensure supply of HF medications to patients in need.
Intervention Type
Other
Intervention Name(s)
Digital health intervention (Medly Uganda) plus enhanced HF clinical care (Core-HF)
Intervention Description
A patient-facing mobile health application designed to improve self-care will be provided to the study participant, which will operate on all mobile devices. This will be introduced after the Core-HF intervention has been delivered.
Primary Outcome Measure Information:
Title
Change in Self-Care of Heart Failure Index (SCHFI)
Description
The SCHFI v7.23 is a validated 39-item instrument hat assesses maintenance, management, and self-confidence of heart failure self-care. Scores range from 0-100 with higher scores indicating improved self care.
Time Frame
baseline, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months
Title
Clinical Effectiveness
Description
A composite of the number of participants with mortality and HF hospitalization will be used to assess clinical effectiveness. This outcome is the most widely used composite clinical endpoint in HF trials globally.
Time Frame
baseline, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months
Secondary Outcome Measure Information:
Title
Participant fidelity to self-care assessed by medication adherence
Description
Participant fidelity will be assessed by self report administered by the Research Assistant.
Time Frame
up to 36 months
Title
Participant fidelity to self-care assessed by optimal HF medication dosing
Description
Participant fidelity to self-care assessed by the percentage of participants that achieve optimal HF medication dosing assessed by self report
Time Frame
up to 36 months
Title
Participant fidelity to self-care assessed by self report
Description
Participant fidelity to self-care assessed by self reported adherence to dietary sodium restriction and exercise recommendations
Time Frame
up to 36 months
Title
Facility fidelity to implementation strategy assessed by vital sign checks
Description
Facility fidelity to implementation strategy will be assessed by the percentage of participants receiving vital sign checks
Time Frame
up to 36 months
Title
Change in blood pressure
Description
Facility fidelity to implementation strategy will be assessed by change in blood pressure. Lower blood pressure indicates a positive outcome.
Time Frame
baseline, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months
Title
Change in weight
Description
Facility fidelity to implementation strategy will be assessed by change in weight measured in pounds. Lower weight indicates a positive outcome.
Time Frame
baseline, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months
Title
Change in resting pulse
Description
Facility fidelity to implementation strategy will be assessed by change in resting pulse measured in beats per minute. Slower pulse indicates a positive outcome.
Time Frame
baseline, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months
Title
Percentage of planned echo training sessions conducted with post-training participant feedback
Description
Facility fidelity to implementation strategy will be assessed by the percentage of planned echo training sessions conducted with post-training participant feedback
Time Frame
up to 36 months
Title
Facility fidelity to implementation strategy assessed by the adherence to medications
Description
Facility fidelity to implementation strategy will be assessed by the prescribing-to-dispensing ratio of HF medications at facility pharmacy by self report
Time Frame
up to 36 months
Title
Change in 6-minute walk test
Description
The 6-minute walk test monitors physical conditioning. It measures the distance an individual can walk over a total of six minutes on a hard, flat surface. The individual can self-pace and rest as needed as they walk back and forth along a marked course. The participant can use an assistive walking device they normally use, such as a cane. The minimum clinically important difference in 6-minute walk distance is approximately 30 meters, a difference that is associated with mortality.
Time Frame
baseline, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months
Title
Change in Pro-NT Brain Natriuretic Peptide (Pro-NT BNP)
Description
Levels of Pro-NT BNP, a widely used prognostic marker in HF, will be measured in blood samples in pg/mL. Lower values indicate a positive outcome.
Time Frame
baseline, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months
Title
Change in Left Ventricular Ejection Fraction
Description
Left ventricular ejection fraction (LVEF) is a widely-recognized clinical prognostic marker for heart failure patients. It is measured as a percentage. Possible range is 0-100. Low is <50%. High is >=50%. LVEF is measured by echocardiogram using Simpson biplane formula
Time Frame
6 months, 18 months and 36 months
Title
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ)
Description
The KCCQ is a 12-item questionnaire that measures symptoms, physical and social limitations, and quality of life in participants with heart failure. KCCQ scores are scaled from 0 to 100, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent.
Time Frame
baseline, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months
Title
Change in EuroQol -5D (EQ-5D)
Description
EQ-5D 5L is a standardized participant completed questionnaire that measures health-related quality of life. It is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions. A utility score was obtained by using a weighted combination of the levels of the five dimension-scales.
Time Frame
baseline, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months
Title
Change in Patient Health Questionnaire-9 (PHQ-9)
Description
Health-related quality of life will be assessed using the PHQ-9. PHQ-9 is a 9-item validated questionnaire used to screen for depression with a range of scores from 0-45. A cumulative score of ≥10 is considered positive with lower scores indicating no or mild anxiety.
Time Frame
baseline, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of New York Heart Association (NYHA) Class II-III HF Access to a mobile phone Basic reading skills in 1 of the offered languages, as determined by their clinical care provider. Languages will include: Lusoga in Jinja, Runyankole in Mbarara, Luganda in Masaka, Rutooro in Fort Portal, Acholi in Gulu, and Alur in Lira in addition to English. Exclusion Criteria: Any individual not meeting the above inclusion criteria Inability to provide informed consent, as determined by the nurse manager Active medical condition requiring hospitalization, such as cardiac ischemia (acute electrocardiographic changes and/or positive biomarkers, if available), syncope, or significant fluid overload Echocardiography findings that do not support a diagnosis of HF as determined during a study visit. This exclusion might occur following enrollment and new patients will be consented and enrolled to compensate for these exclusions.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jeremy Schwartz, MD
Phone
203-680-1598
Email
jeremy.schwartz@yale.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeremy Schwartz, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fort Portal Regional Referral Hospital
City
Fort Portal
Country
Uganda
Facility Name
Gulu Regional Referral Hospital
City
Gulu
Country
Uganda
Facility Name
Jinja Regional Referral Hospital
City
Jinja
Country
Uganda
Facility Name
Lira Regional Referral Hospital
City
Lira
Country
Uganda
Facility Name
Masaka Regional Referral Hospital
City
Masaka
Country
Uganda
Facility Name
Mbarara Regional Referral Hospital
City
Mbarara
Country
Uganda

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

ImpleMEntation of a Digital-first Care deLiverY Model for Heart Failure in Uganda

We'll reach out to this number within 24 hrs